Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Phone+1-978-2564200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees857
OptionableNot Optionable
Cynosure (NASDAQ:CYNO) Frequently Asked Questions
What is Cynosure's stock symbol?
Cynosure trades on the NASDAQ under the ticker symbol "CYNO."
How were Cynosure's earnings last quarter?
Cynosure, Inc. (NASDAQ:CYNO) issued its quarterly earnings results on Tuesday, July, 26th. The medical equipment provider reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.07. The medical equipment provider had revenue of $110.30 million for the quarter, compared to analyst estimates of $101.31 million. The firm's quarterly revenue was up 31.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.30 earnings per share. View Cynosure's Earnings History.
Has Cynosure been receiving favorable news coverage?
Press coverage about CYNO stock has trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cynosure earned a news impact score of 1.1 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Cynosure?
Shares of CYNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynosure's official website?
How can I contact Cynosure?
Cynosure's mailing address is 5 Carlisle Rd, WESTFORD, MA 01886-3601, United States. The medical equipment provider can be reached via phone at +1-978-2564200.
MarketBeat Community Rating for Cynosure (NASDAQ CYNO)
MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe CYNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
